Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

256
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
256
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

421
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
421

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One Face, Three Solutions: Structural Convergence in PD-L1 Inhibition across Antibodies, Macrocycles, and Small Molecules.

Journal of medicinal chemistry·2026
Same author

<i>APOE</i> ε4-specific associations between agitation, cerebrospinal fluid biomarkers, and cognitive decline in cognitively impaired patients.

Journal of Alzheimer's disease : JAD·2026
Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026
Same author

Neurocritical progression in amyotrophic lateral sclerosis: pathological relevance and validation.

Open life sciences·2026
Same author

Comparative Transcriptomics Reveals an Extracellular Worm Argonaute as an Ancestral Regulator of LTR Retrotransposons.

Genome biology and evolution·2026
Same author

Biosynthesized Silk-Amyloid-Mussel Proteins as Dissolution Recyclable Materials With Tunable Supercontraction.

Advanced materials (Deerfield Beach, Fla.)·2026
Same journal

Semisynthesis of Mycothiazole Analogs having Distinct Bioactivity.

ACS medicinal chemistry letters·2026
Same journal

Investigation on the Cytotoxicity of Hydroxycinnamic and Hydroxybenzoic Acid-Based Natural Antioxidant Conjugated Terpyridine Analogues toward Triple-Negative Breast Cancer.

ACS medicinal chemistry letters·2026
Same journal

Beyond Neddylation Inhibition: X‑ray Structures Reveal Carbonic Anhydrase Isoform Selectivity of Pevonedistat.

ACS medicinal chemistry letters·2026
Same journal

Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.

ACS medicinal chemistry letters·2026
Same journal

Controlling Neuroplasticity Across Scales: Constrained Serotonergic Agonists, Neuroplastogens, and Adaptive Neuromodulation.

ACS medicinal chemistry letters·2026
Same journal

Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in Cancer.

ACS medicinal chemistry letters·2026
See all related articles

Related Experiment Video

Updated: Aug 28, 2025

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

610

Multicomponent Macrocyclic IL-17a Modifier.

Eman Abdelraheem1,2, Max Lubberink1, Wenja Wang1

  • 1Department of Pharmacy, Drug Design Group, University of Groningen, A. Deusinglaan 1, Groningen 9700 AV, The Netherlands.

ACS Medicinal Chemistry Letters
|September 15, 2022
PubMed
Summary
This summary is machine-generated.

Researchers developed novel macrocyclic compounds targeting Interleukin-17a (IL-17a), a key inflammation mediator. This work advances small-molecule antagonists, offering a new therapeutic avenue beyond current antibody treatments for inflammatory diseases.

More Related Videos

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
07:46

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

3.3K
Isolation and Th17 Differentiation of Na&#239;ve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

34.7K

Related Experiment Videos

Last Updated: Aug 28, 2025

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro
12:08

Retroviral CRISPR/Cas9-Mediated Gene Targeting for the Study of Th17 Differentiation in Vitro

Published on: November 15, 2024

610
Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation
07:46

Author Spotlight: Achieving High-Purity In Vitro Differentiation of Th17 Cells Using Cytokine Concentration Modulation

Published on: October 25, 2024

3.3K
Isolation and Th17 Differentiation of Na&#239;ve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

34.7K

Area of Science:

  • Medicinal Chemistry
  • Immunology
  • Drug Discovery

Background:

  • Interleukin-17a (IL-17a) is a critical cytokine in inflammatory pathways, with existing treatments primarily relying on antibody therapies.
  • The development of small-molecule IL-17a antagonists represents a significant emerging area in pharmaceutical research, with several candidates progressing to clinical trials.

Purpose of the Study:

  • To design, discover, synthesize, and screen novel macrocyclic compounds with the potential to inhibit IL-17a.
  • To explore the pharmacophore model of existing IL-17a modifiers and identify new binding strategies.

Main Methods:

  • Utilized pharmacophore analysis and virtual screening to identify lead macrocyclic compounds.
  • Employed resynthesis and protein biophysics techniques to characterize compound interactions with IL-17a.
  • Integrated computational and experimental approaches in a drug discovery pipeline.

Main Results:

  • Identified a shared pharmacophore model among known IL-17a modifiers, suggesting conserved binding mechanisms.
  • Successfully designed and synthesized novel macrocyclic compounds targeting IL-17a.
  • Discovered a potent macrocyclic IL-17a modifier through a comprehensive screening and validation process.

Conclusions:

  • Macrocyclic compounds represent a viable class of small-molecule inhibitors for IL-17a.
  • The developed pipeline effectively identifies potent modulators of IL-17a.
  • These findings contribute to the advancement of targeted therapies for IL-17a-mediated inflammatory conditions.